Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 19, Pages 8464-8476Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm300930n
Keywords
-
Categories
Funding
- National Institutes of Health [GM086893]
- U.S. Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]
- NSF
- NIH/NIGMS via NSF [DMR-0936384]
- NIH/NIGMS [GM103485]
Ask authors/readers for more resources
Human cytochrome P450 aromatase catalyzes with high specificity the synthesis of estrogens from androgens. Aromatase inhibitors (AIs) such as exemestane, 6-methylideneandrosta-1,4-diene-3,17-dione, are preeminent drugs for the treatment of estrogen-dependent breast cancer. The crystal structure of human placental aromatase has shown an androgen-specific active site. By utilization of the structural data, novel C6-substituted androsta-1,4-diene-3,17-dione inhibitors have been designed. Several of the C6-substituted 2-alkynyloxy compounds inhibit purified placental aromatase with IC50 values in the nanomolar range. Antiproliferation studies in a MCF-7 breast cancer cell line demonstrate that some of these compounds have EC50 values better than 1 nM, exceeding that for exemestane. X-ray structures of aromatase complexes of two potent compounds reveal that, per their design, the novel side groups protrude into the opening to the access channel unoccupied in the enzyme-substrate/exemestane complexes. The observed structure-activity relationship is borne out by the X-ray data. Structure-guided design permits utilization of the aromatase-specific interactions for the development of next generation AIs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available